Lipopolysaccharide exposure augments isoniazide-induced liver injury

Journal of Applied Toxicology

Volumn 34, Issue 12, 2014, Pages 1436-1442

  Su, Yijing ^a   Zhang, Yun ^b   Chen, Mi ^a   Jiang, Zhenzhou ^a   Sun, Lixin ^a   Wang, Tao ^a   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b QILU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Cholestasis; Hepatotoxicity; Idiosyncratic drug induced liver injury; Isoniazide; Lipopolysaccharide

Indexed keywords

BILE ACID; CHOLESTEROL; ISONIAZID; LIPOPOLYSACCHARIDE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BLOOD; DOSE RESPONSE; DRUG POTENTIATION; DRUG-INDUCED LIVER INJURY; IMMUNOLOGY; LIVER FUNCTION TEST; MALE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTITUBERCULAR AGENTS; BILE ACIDS AND SALTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG-INDUCED LIVER INJURY; ISONIAZID; LIPOPOLYSACCHARIDES; LIVER FUNCTION TESTS; MALE; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911433119     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2979     Document Type: Article

References (31)

1. Amacher DE. 2012. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert. Opin. Drug. Metab. Toxicol. 8: 335-347.
2. Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, Roth RA. 2000. Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury. Toxicol. Sci. 55: 444-452.
3. Bell LN, Chalasani N. 2009. Epidemiology of idiosyncratic drug-induced liver injury. Semin. Liver. Dis. 29: 337-347.
4. Bogdanos DP, Baum H, Vergani D, Burroughs AK. 2010. The role of E. coli infection in the pathogenesis of primary biliary cirrhosis. Dis. Markers. 29: 301-311.
5. Boyer JL. 1980. New concepts of mechanisms of hepatocyte bile formation. Physiol. Rev. 60: 303-326.
6. Chiang JY. 2009. Bile acids: regulation of synthesis. J. Lipid. Res. 50: 1955-1966.
7. Cunningham K, Claus SP, Lindon JC, Holmes E, Everett JR, Nicholson JK, Coen M. 2012. Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response. J. Proteome. Res. 11: 4630-4642.
8. Deng X, Luyendyk JP, Ganey PE, Roth RA. 2009. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol. Rev. 61: 262-282.
9. Elferink MG, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJ, Meijer DK, Groothuis GM. 2004. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am. J. Physiol. Gastrointest. Liver. Physiol. 287: G1008-1016.
10. Hasegawa T, Takagi K, Kitaichi K. 1999. Effects of bacterial endotoxin on drug pharmacokinetics. Nagoya. J. Med. Sci. 62: 11-28.
11. Kaplowitz N. 2005. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug. Discov. 4: 489-499.
12. Li T, Chiang JY. 2012. Bile acid signaling in liver metabolism and diseases. J. Lipids. 2012. doi: 10.1155/2012/754067.
13. Li X, Zhu X. 2007. Advance in the research on several nuclear receptors related to bile acid metabolism. Chin. J. Pharmacol. Toxicol. 21: 152-156.
14. Lima Mde F, Melo HR. 2012. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica 28(4): 698-708.
15. Liu L, Jiang Z, Huang X, Liu J, Zhang J, Xiao J, Bao Q, Wen J, Zhang S, Zhu D, Zhang P, Zhang L. 2011. Disappearance of sexual dimorphism in triptolide metabolism in monosodium glutamate treated neonatal rats. Arzneimittelforschung 61: 98-103.
16. Luyendyk JP, Shores KC, Ganey PE, Roth RA. 2002. Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. 68: 220-225.
17. Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. 2003. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307: 9-16.
18. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. 2011. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther. 89: 911-914.
19. Preziosi P. 2007. Isoniazid: metabolic aspects and toxicological correlates. Curr. Drug. Metab. 8: 839-851.
20. Roth RA, Harkema JR, Pestka JP, Ganey PE. 1997. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol. Appl. Pharmacol. 147: 300-311.
21. Roy PD, Majumder M, Roy B. 2008. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 9: 311-321.
22. Shaw PJ, Ganey PE, Roth RA. 2009. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J. Pharmacol. Exp. Ther. 330: 72-78.
23. Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL. 2006. Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther. 318(2): 881-889.
24. Uetrecht J. 2007. Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol. 47: 513-539.
25. Uetrecht J. 2008. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21: 84-92.
26. Wagner M, Zollner G, Trauner M. 2009. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51: 565-580.
27. Yee SB, Kinser S, Hill DA, Barton CC, Hotchkiss JA, Harkema JR, Ganey PE, Roth RA. 2000. Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol. Appl. Pharmacol. 166: 173-185.
28. Zhang Y, Edwards PA. 2008. FXR signaling in metabolic disease. FEBS Lett. 582: 10-18.
29. Zhang Y, Jiang Z, Su Y, Chen M, Li F, Liu L, Sun L, Wang Y, Zhang S, Zhang L. 2013. Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats. J Appl Toxicol. 33(8): 807-819.
30. Zinchuk VS, Okada T, Akimaru K, Seguchi H. 2002. Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. Am J Physiol Gastrointest Liver Physiol. 282(3): G540-8.
31. Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. 2009. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol. Sci. 108: 184-193.